Fusion Antibodies (LON:FAB) Trading 9.2% Higher – Here’s Why

Fusion Antibodies plc (LON:FAB)’s share price shot up 9.2% during mid-day trading on Tuesday . The company traded as high as GBX 17.29 and last traded at GBX 16.66. 1,439,924 shares traded hands during trading, an increase of 25% from the average session volume of 1,150,315 shares. The stock had previously closed at GBX 15.25.

Fusion Antibodies Stock Performance

The company has a market cap of £19.89 million, a price-to-earnings ratio of -11.67 and a beta of 0.49. The company has a debt-to-equity ratio of 2.40, a current ratio of 3.87 and a quick ratio of 2.36. The firm has a fifty day simple moving average of GBX 13.84 and a 200 day simple moving average of GBX 12.13.

Fusion Antibodies (LON:FAB) last issued its quarterly earnings data on Monday, November 24th. The company reported GBX (0.50) earnings per share for the quarter. Fusion Antibodies had a negative return on equity of 137.11% and a negative net margin of 195.95%. On average, sell-side analysts expect that Fusion Antibodies plc will post -129.9999875 earnings per share for the current fiscal year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation.